Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...
Shares of Axsome Therapeutics ( AXSM 4.07%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...
BofA Securities analyst Jason Gerberry increased the price target for Axsome Therapeutics (NASDAQ:AXSM) shares to $167 from the previous $143, while reiterating a Buy rating on the stock. This aligns ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...
Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Deutsche Bank (ETR:DBKGn) initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) shares, assigning a Buy rating and setting a price target of $176.00. The new coverage comes with a positive outlook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback